Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says

28th September 2017 Uncategorised 0

Megamerger deal talk has swirled around Novartis as the Swiss drugmaker eyes its operations—particularly Alcon—for cash-generating sales or spinoffs. But all along, CEO Joe Jimenez has been pledging bolt-on deals instead, and the latest buzz says he has one on tap.

More: Why would Novartis buy a .6B radiotherapy maker? Its neuroendocrine franchise, analyst says
Source: fierce